Skin AgingNCT07390305
Multidimensional Correlation Study on Skin Aging in Menopausal Women
An observational study of Skin Aging and Reproductive Aging, run by ChinaNorm at 1 site in China.
Trial summary
Primary Objective: This study primarily aims to compare skin aging characteristics between women at different stages of reproductive aging in both sun-exposed and non-exposed areas, based on skin indicators collected during a single laboratory visit. Read more about this study
- Who is it for?
- Ages 18 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Skin Aging, Reproductive Aging, Menopause
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 11 Nov 2025to 20 Jan 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: This study enrolled adult women categorized into four distinct groups based on their reproductive aging stage according to the STRAW+10 staging system: a Young Control Group (aged 18-25, biological daughters of participants in the older groups, with regular menstrual cycles), an Early Perimenopausal Group (aged 45-50, with a persistent change in menstrual cycle length >7 days), a Late Perimenopausal Group (aged 50-55, experiencing ≥2 consecutive cycles of ≥60 days or amenorrhea of ≥60 days), and a Postmenopausal Group (aged 55-60, with the last menstrual period occurring at least 12 months prior). All participants were recruited as mother-daughter pairs, where the young control group consisted of the biological daughters of participants in the late perimenopausal and postmenopausal groups .
Who may be able to join
- Participants must possess basic Chinese literacy skills (reading comprehension and expression) to complete questionnaires independently.
- Voluntary participation and signed informed consent.
- Willingness to comply with all study requirements and assessments.
- Early Perimenopausal Group：
- Healthy women aged 45-50 (±3) years.
- STRAW Stage -2 / Early Perimenopause: Experiencing a persistent change in menstrual cycle length of >7 days from their normal cycle, but with no occurrence of 60 or more days of amenorrhea (i.e., still having menstrual periods).
Show all 29Show fewer
- Late Perimenopausal Group：
- Healthy women aged 50-55 (±3) years.
- STRAW Stage -1 / Late Perimenopause: Experiencing ≥2 consecutive cycles with a length of ≥60 days, or the presence of ≥60 days of amenorrhea.
- 6) Postmenopausal Group：
- <!-- -->
- Healthy women aged 55-60 (±3) years.
- STRAW Stage +1 / Postmenopause: Last menstrual period occurred at least 12 months prior.
- 7）Young Control Group：
- Healthy women aged 18-25 (±3) years.
- Biological daughters of participants in either the Late Perimenopausal Group or the Postmenopausal Group.
- Regular menstrual cycle, with a cycle length ranging between 25-35 days. Exclusion Criteria
- Presence of open wounds, clearly visible scars, acne marks, or other significant skin imperfections at the measurement sites.
- History of skin diseases affecting the evaluation of the study areas (e.g., psoriasis, atopic dermatitis, skin cancer).
- Women who are currently pregnant or breastfeeding.
- Use of systemic estrogen or progesterone hormone replacement therapy within the past 6 months.
- Presence of acute or severe chronic diseases currently under treatment.
- Any known condition that significantly impairs cognitive or behavioral abilities.
- Considered by the investigator or qualified professional to have other medical or specific reasons that may interfere with the evaluation of study results.
- Early Perimenopausal Group \& Late Perimenopausal Group \& Postmenopausal Group:
- Current use of systemic hormone replacement therapy (HRT). b) Topical application of anti-aging products (e.g., retinoids, alpha/beta hydroxy acids) on the measurement areas within the past 3 months.
- History of breast cancer or oophorectomy. 9） Young Control Group:
- Currently planning for pregnancy, pregnant, or lactating.
- Diagnosis of Polycystic Ovary Syndrome (PCOS).
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai China-norm Quality Technical Service Co., Ltd.
Shanghai, Shanghai Municipality, 200072
About this study
Official title: Study on the Correlation Between Skin Aging in Exposed / Non Exposed Areas and Menopausal Symptoms, Emotions, and Sleep in Menopausal Women
Primary Objective:
This study primarily aims to compare skin aging characteristics between women at different stages of reproductive aging in both sun-exposed and non-exposed areas, based on skin indicators collected during a single laboratory visit. Furthermore, through a 30-day at-home tracking period (for the late-stage and postmenopausal groups) or one menstrual cycle (for the early-stage and young group), we seek to analyze the temporal dynamics of changes in skin condition, mood, sleep quality, and menopausal hot flashes.
Read more
Secondary Objective:
The secondary objective is to examine differences in skin conditions across life stages by recruiting mother-daughter pairs (where the young group consists of the biological daughters of the late-stage and postmenopausal groups). The core focus is to leverage shared genetic backgrounds to explore how skin characteristics, particularly in different body areas, may change over time or in response to hormonal fluctuations. By comparing these characteristics across age groups, this study seeks to identify key variation patterns and their contributing factors, thereby laying the groundwork for further mechanistic investigations and practical applications.
- Conditions
- Skin Aging, Reproductive Aging, Menopause, Genetic Factors
- Keywords
- Skin Aging, Reproductive Aging, Menopause, Exposed/Non-Exposed Skin Sites, Hormonal Fluctuations, Genetic Factors, Mother-Daughter Pairs, Longitudinal Tracking, Skin Biophysical Properties
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Early Perimenopausal Group | Not described | |
| Late Perimenopausal Group | Not described | |
| Postmenopausal Group | Not described | |
| Young Control Group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Assessment
This assessment involves a clinical evaluation of skin aging degree performed by dermatologists at the T1 time point. The evaluation is conducted according to the skin aging scales outlined in the "Human Skin Aging Evaluation Standard" . It targets both exposed areas (face, dorsum of hands) and non-exposed areas (inner side of the upper arm, outer upper hip region) to differentiate between intrinsic and extrinsic aging factors. Specific skin lesions, such as epidermal/vascular proliferations, are assessed as separate individual items.
Measured: The assessment is performed as a single evaluation at the T1 (baseline) laboratory visit .
Skin Wrinkle and Smoothness Assessment
This assessment quantitatively evaluates skin surface topography using a dedicated imaging system. The instrument captures high-resolution grayscale images of the skin's surface. The built-in Skin Evaluation Living Skin (SELS) software then analyzes the image to extract objective numerical values for key parameters. The primary indicators measured are: SEw (Surface Evaluation of Wrinkles), where a higher value indicates more pronounced wrinkles; and SEsm (Surface Evaluation of Smoothness), where a lower value indicates smoother skin.
Measured: The assessment is conducted as a single measurement at the T1 (baseline) time point .
Skin Color Measurement with Colorimeter
This assessment quantitatively measures skin color using the Colorimeter probe. The instrument emits white LED light from a ring-shaped configuration to ensure even illumination of the skin surface. The light scatters upon contact, with some penetrating the skin and some being reflected. The probe captures the reflected light, and the raw data is corrected via a specialized color matrix to approximate standard values. The skin color is expressed in XYZ tristimulus values and converted into the standardized CIE Lab* color space parameters. The L* value represents lightness (brightness) on a black-white axis. The a* value indicates the position on the red-green axis (often interpreted as erythema or red pigment), and the b* value indicates the position on the blue-yellow axis (often associated with yellow pigment). Additionally, the Individual Typology Angle (ITA°) value is automatically calculated, where a higher ITA° value indicates lighter skin.
Measured: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit.
Skin Elasticity Measurement with Cutometer® MPA580
The Cutometer® MPA580 assesses skin mechanical properties based on the suction and stretch principle. It applies a controlled negative pressure to the skin, drawing it into the probe aperture. The depth of skin deformation is measured optically by the ratio of light emitted to light received within the probe. Key parameters extracted for this study include R2 (Gross Elasticity) and F4 (Firmness). The R2 value, representing the ratio of total retraction to total deformation, approaches 1 for highly elastic skin. The F4 value corresponds to the skin's firmness or resistance to the suction force; a lower F4 value indicates firmer, more resistant skin .
Measured: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit .
Skin Ultrasound Diagnostic System Ultrascan UC22
The Ultrascan UC22 is a high-frequency ultrasound imaging system used for non-invasive assessment of skin microstructure. It operates by emitting a 22 MHz ultrasound signal into the skin; the echoes reflected from internal skin structures are captured and digitally processed to generate high-resolution, cross-sectional images. This allows for the in vivo measurement of key parameters related to skin aging, primarily skin thickness and skin density (which correlates with collagen density and tissue structure). This tool is particularly valuable for objectively evaluating intrinsic skin aging and the efficacy of cosmetic interventions in research settings.
Measured: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit.
Skin Moisture Loss Meter Vapometer
he Vapometer is a portable device designed to measure Transepidermal Water Loss (TEWL), a key indicator of the skin barrier's functional integrity. Its operation is based on the closed-chamber principle. The core of the instrument is a highly sensitive humidity sensor located within a cylindrical measurement chamber. During measurement, this chamber is sealed against the skin surface, creating a microenvironment protected from ambient air currents. The sensor monitors the increase in relative humidity (RH) inside the chamber caused by the evaporation of water from the skin. The TEWL value, expressed in grams per square meter per hour (g/m²h), is automatically calculated from this rate of humidity increase . This method is particularly suitable for detecting changes in skin water loss and is widely used in dermatological research and cosmetic efficacy evaluations.
Measured: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit .
Skin Hemoglobin Measurement with Mexameter® MX18
The Mexameter® MX18 is a specialized probe that quantitatively assesses skin color by measuring the two primary chromophores: melanin and hemoglobin. It operates on the principle of light absorption and reflection.
Measured: The assessment is performed as a single measurement at the T1 (baseline) laboratory visit .
Intelligent Skin Analyzer Skinmeter
The Skinmeter is a portable device designed for the non-invasive assessment of key skin physiological parameters. For the purpose of this study, the primary focus of the measurement is on the skin hydration (moisture) parameter.
Measured: The measurement is performed at three designated time points during the study: T1( Day1),T2(Day 15), and T3(Day 30).
Skin Sebum Measurement with Sebum-Test Paper
This method quantitatively assesses skin sebum (oil) content using a specialized oil-absorbent test paper and subsequent image analysis.
Measured: The measurement is performed at three designated time points during the study: T1( Day1),T2(Day 15), and T3(Day 30).
Sleep Duration Recording
This component utilizes the smart band monitoring algorithm to objectively record participants' sleep patterns. The algorithm employs a multi-modal approach, integrating data from accelerometers (to monitor body movement) and photoplethysmography (PPG) sensors (to monitor heart rate and heart rate variability) . By analyzing the correlation between physiological signals such as body movement, heart rate, and their variability with sleep states, it constructs a fusion algorithm model to accurately identify sleep stages and calculate total sleep duration . This non-invasive method allows for convenient, at-home sleep monitoring over extended periods.
Measured: Sleep data is collected continuously throughout the entire tracking period of the study.Day1 to Day 30.
Secondary outcomes (6)
BMI
Body Mass Index (BMI) is a widely used international standard for assessing body weight and health status. It is a numerical value calculated from an individual's weight and height.
Measured: BMI is measured during the baseline laboratory visit.
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire widely used to assess subjective sleep quality over a specified period.
Measured: The PSQI questionnaire will be administered at three designated time points during the study: Day1, Day15, and Day30. At each assessment, participants will be asked to recall and report on their sleep quality and disturbances over the past 1 week .
Generalized Anxiety Disorder-7 (GAD-7)
The Generalized Anxiety Disorder-7 (GAD-7) is a self-report questionnaire utilized for screening and assessing the severity of generalized anxiety disorder. As a component of the Patient Health Questionnaire (PHQ) series, it consists of 7 items that inquire about the frequency of core anxiety symptoms-such as feeling nervous, anxious, or on edge, and being unable to control worrying-over a specified period. Respondents rate each item on a 4-point scale. The total score (ranging from 0 to 21) helps categorize anxiety severity, facilitating initial assessment and monitoring of symptoms.
Measured: he questionnaire is administered at three designated time points during the study: T1(Day1), T2(Day15), and T3(Day30). At each assessment, participants are asked to recall and report on their experiences over the past two weeks .
Patient Health Questionnaire-8 Items (PHQ-8)
The Patient Health Questionnaire-8 (PHQ-8) is a standardized self-report instrument widely used to screen for and measure the severity of depressive symptoms . It consists of 8 items that correspond to the diagnostic criteria for depressive disorders. Respondents rate the frequency of each symptom over a specified recall period on a 4-point scale (0 to 3). The total score, ranging from 0 to 24, helps categorize depressive severity, from none to severe . It is a reliable and valid tool for use in both clinical and research settings.
Measured: The questionnaire is administered at three specific time points during the study: T1 (Day1), T2(Day15), and T3(Day30). At each assessment, participants are asked to report on their experiences over the past two weeks .
Assessment of Hot Flash Frequency and Impact on Daily Life
This questionnaire is designed to assess the frequency and subjective impact of hot flashes (also known as vasomotor symptoms) on an individual's daily life. The instrument draws on core concepts from established tools, including the Kupperman Menopausal Index (KMI) and the Hot Flush Rating Scale (HFRS). It evaluates two primary dimensions: 1) the frequency of hot flash episodes over a specified period, and 2) the degree of interference these symptoms cause to various aspects of daily living, such as work, mood, sleep, and social activities. The aim is to provide a quantitative and qualitative measure of the burden of hot flashes
Measured: This questionnaire is to be completed daily throughout the testing period. Participants are asked to recall and report on their hot flash experiences over the past 24 hours.From Day1 to Day30.
Ultraviolet (UV) Exposure Questionnaire
This component quantitatively evaluates participants' real-life exposure to ultraviolet (UV) radiation and their photoprotection practices over a specified period. It encompasses key dimensions such as: 1. Sun Protection Behaviors: Frequency of use and types of physical protection (e.g., wide-brimmed hats, long-sleeved clothing) and sunscreen (including Sun Protection Factor, or SPF). 2. Outdoor Activity Patterns: Time spent outdoors for both occupational and recreational activities. The aim is to estimate individual UV exposure dose and identify potential risk factors for skin damage.
Measured: The questionnaire assesses UV exposure behaviors and sun protection habits over the past 1 month and is administered at the T1 (baseline) laboratory visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start11 Nov 2025
- Primary completion20 Jan 2026
- Study completion20 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- ChinaNorm
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07390305
- Sponsor's protocol ID
- W25006001
- Status last verified
- Feb 2026
- First submitted
- 12 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Correlation Between Skin Aging in Exposed / Non Exposed Areas and Menopausal Symptoms, Emotions, and Sleep in Menopausal Women
- ClinicalTrials.gov ID
- NCT07390305
- Acronym / sponsor ID
- W25006001
- Conditions
- Skin Aging, Reproductive Aging, Menopause, Genetic Factors
- Keywords
- Skin Aging, Reproductive Aging, Menopause, Exposed/Non-Exposed Skin Sites, Hormonal Fluctuations, Genetic Factors, Mother-Daughter Pairs, Longitudinal Tracking
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- ChinaNormIndustry (pharma, biotech, devices)
- Study start
- 11 Nov 2025 (actual)
- Primary completion
- 20 Jan 2026 (actual)
- Study completion
- 20 Jan 2026 (actual)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary Objective:
This study primarily aims to compare skin aging characteristics between women at different stages of reproductive aging in both sun-exposed and non-exposed areas, based on skin indicators collected during a single laboratory visit. Furthermore, through a 30-day at-home tracking period (for the late-stage and postmenopausal groups) or one menstrual cycle (for the early-stage and young group), we seek to analyze the temporal dynamics of changes in skin condition, mood, sleep quality, and menopausal hot flashes.
Secondary Objective:
The secondary objective is to examine differences in skin conditions across life stages by recruiting mother-daughter pairs (where the young group consists of the biological daughters of the late-stage and postmenopausal groups). The core focus is to leverage shared genetic backgrounds to explore how skin characteristics, particularly in different body areas, may change over time or in response to hormonal fluctuations. By comparing these characteristics across age groups, this study seeks to identify key variation patterns and their contributing factors, thereby laying the groundwork for further mechanistic investigations and practical applications.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Early Perimenopausal Group | – | – |
| Late Perimenopausal Group | – | – |
| Postmenopausal Group | – | – |
| Young Control Group | – | – |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- This study enrolled adult women categorized into four distinct groups based on their reproductive aging stage according to the STRAW+10 staging system: a Young Control Group (aged 18-25, biological daughters of participants in the older groups, with regular menstrual cycles), an Early Perimenopausal Group (aged 45-50, with a persistent change in menstrual cycle length >7 days), a Late Perimenopausal Group (aged 50-55, experiencing ≥2 consecutive cycles of ≥60 days or amenorrhea of ≥60 days), and a Postmenopausal Group (aged 55-60, with the last menstrual period occurring at least 12 months prior). All participants were recruited as mother-daughter pairs, where the young control group consisted of the biological daughters of participants in the late perimenopausal and postmenopausal groups .
Key inclusion criteria (29 listed)
- Participants must possess basic Chinese literacy skills (reading comprehension and expression) to complete questionnaires independently.
- Voluntary participation and signed informed consent.
- Willingness to comply with all study requirements and assessments.
- Early Perimenopausal Group：
- Late Perimenopausal Group：
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Clinical Assessment
Time frame: The assessment is performed as a single evaluation at the T1 (baseline) laboratory visit .
This assessment involves a clinical evaluation of skin aging degree performed by dermatologists at the T1 time point. The evaluation is conducted according to the skin aging scales outlined in the "Human Skin Aging Evaluation Standard" . It targets both exposed areas (face, dorsum of hands) and non-exposed areas (inner side of the upper arm, outer upper hip region) to differentiate between intrinsic and extrinsic aging factors. Specific skin lesions, such as epidermal/vascular proliferations, are assessed as separate individual items.
Skin Wrinkle and Smoothness Assessment
Time frame: The assessment is conducted as a single measurement at the T1 (baseline) time point .
This assessment quantitatively evaluates skin surface topography using a dedicated imaging system. The instrument captures high-resolution grayscale images of the skin's surface. The built-in Skin Evaluation Living Skin (SELS) software then analyzes the image to extract objective numerical values for key parameters. The primary indicators measured are: SEw (Surface Evaluation of Wrinkles), where a higher value indicates more pronounced wrinkles; and SEsm (Surface Evaluation of Smoothness), where a lower value indicates smoother skin.
Skin Color Measurement with Colorimeter
Time frame: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit.
This assessment quantitatively measures skin color using the Colorimeter probe. The instrument emits white LED light from a ring-shaped configuration to ensure even illumination of the skin surface. The light scatters upon contact, with some penetrating the skin and some being reflected. The probe captures the reflected light, and the raw data is corrected via a specialized color matrix to approximate standard values. The skin color is expressed in XYZ tristimulus values and converted into the standardized CIE Lab* color space parameters. The L* value represents lightness (brightness) on a black-white axis. The a* value indicates the position on the red-green axis (often interpreted as erythema or red pigment), and the b* value indicates the position on the blue-yellow axis (often associated with yellow pigment). Additionally, the Individual Typology Angle (ITA°) value is automatically calculated, where a higher ITA° value indicates lighter skin.
Skin Elasticity Measurement with Cutometer® MPA580
Time frame: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit .
The Cutometer® MPA580 assesses skin mechanical properties based on the suction and stretch principle. It applies a controlled negative pressure to the skin, drawing it into the probe aperture. The depth of skin deformation is measured optically by the ratio of light emitted to light received within the probe. Key parameters extracted for this study include R2 (Gross Elasticity) and F4 (Firmness). The R2 value, representing the ratio of total retraction to total deformation, approaches 1 for highly elastic skin. The F4 value corresponds to the skin's firmness or resistance to the suction force; a lower F4 value indicates firmer, more resistant skin .
Skin Ultrasound Diagnostic System Ultrascan UC22
Time frame: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit.
The Ultrascan UC22 is a high-frequency ultrasound imaging system used for non-invasive assessment of skin microstructure. It operates by emitting a 22 MHz ultrasound signal into the skin; the echoes reflected from internal skin structures are captured and digitally processed to generate high-resolution, cross-sectional images. This allows for the in vivo measurement of key parameters related to skin aging, primarily skin thickness and skin density (which correlates with collagen density and tissue structure). This tool is particularly valuable for objectively evaluating intrinsic skin aging and the efficacy of cosmetic interventions in research settings.
Skin Moisture Loss Meter Vapometer
Time frame: The measurement is performed as a single assessment at the T1 (baseline) laboratory visit .
he Vapometer is a portable device designed to measure Transepidermal Water Loss (TEWL), a key indicator of the skin barrier's functional integrity. Its operation is based on the closed-chamber principle. The core of the instrument is a highly sensitive humidity sensor located within a cylindrical measurement chamber. During measurement, this chamber is sealed against the skin surface, creating a microenvironment protected from ambient air currents. The sensor monitors the increase in relative humidity (RH) inside the chamber caused by the evaporation of water from the skin. The TEWL value, expressed in grams per square meter per hour (g/m²h), is automatically calculated from this rate of humidity increase . This method is particularly suitable for detecting changes in skin water loss and is widely used in dermatological research and cosmetic efficacy evaluations.
Skin Hemoglobin Measurement with Mexameter® MX18
Time frame: The assessment is performed as a single measurement at the T1 (baseline) laboratory visit .
The Mexameter® MX18 is a specialized probe that quantitatively assesses skin color by measuring the two primary chromophores: melanin and hemoglobin. It operates on the principle of light absorption and reflection.
Intelligent Skin Analyzer Skinmeter
Time frame: The measurement is performed at three designated time points during the study: T1( Day1),T2(Day 15), and T3(Day 30).
The Skinmeter is a portable device designed for the non-invasive assessment of key skin physiological parameters. For the purpose of this study, the primary focus of the measurement is on the skin hydration (moisture) parameter.
Skin Sebum Measurement with Sebum-Test Paper
Time frame: The measurement is performed at three designated time points during the study: T1( Day1),T2(Day 15), and T3(Day 30).
This method quantitatively assesses skin sebum (oil) content using a specialized oil-absorbent test paper and subsequent image analysis.
Sleep Duration Recording
Time frame: Sleep data is collected continuously throughout the entire tracking period of the study.Day1 to Day 30.
This component utilizes the smart band monitoring algorithm to objectively record participants' sleep patterns. The algorithm employs a multi-modal approach, integrating data from accelerometers (to monitor body movement) and photoplethysmography (PPG) sensors (to monitor heart rate and heart rate variability) . By analyzing the correlation between physiological signals such as body movement, heart rate, and their variability with sleep states, it constructs a fusion algorithm model to accurately identify sleep stages and calculate total sleep duration . This non-invasive method allows for convenient, at-home sleep monitoring over extended periods.
6 secondary outcomes
BMI
Time frame: BMI is measured during the baseline laboratory visit.
Pittsburgh Sleep Quality Index (PSQI)
Time frame: The PSQI questionnaire will be administered at three designated time points during the study: Day1, Day15, and Day30. At each assessment, participants will be asked to recall and report on their sleep quality and disturbances over the past 1 week .
Generalized Anxiety Disorder-7 (GAD-7)
Time frame: he questionnaire is administered at three designated time points during the study: T1(Day1), T2(Day15), and T3(Day30). At each assessment, participants are asked to recall and report on their experiences over the past two weeks .
Patient Health Questionnaire-8 Items (PHQ-8)
Time frame: The questionnaire is administered at three specific time points during the study: T1 (Day1), T2(Day15), and T3(Day30). At each assessment, participants are asked to report on their experiences over the past two weeks .
Assessment of Hot Flash Frequency and Impact on Daily Life
Time frame: This questionnaire is to be completed daily throughout the testing period. Participants are asked to recall and report on their hot flash experiences over the past 24 hours.From Day1 to Day30.
Ultraviolet (UV) Exposure Questionnaire
Time frame: The questionnaire assesses UV exposure behaviors and sun protection habits over the past 1 month and is administered at the T1 (baseline) laboratory visit.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Skin Aging
Recruiting
Ultraformer MPT Combined With Fractional CO2 Versus Fractional CO2 Alone for Facial Rejuvenation
Skin Aging
Enrolling by invitationEarly Phase 1
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Aging
Not yet recruiting
Effects of Probiotics on Skin Health in Healthy Women
Skin Aging, Dry Skin
Not yet recruiting
Evaluation of MD60002 Device for Facial Skin Aging
Facial Wrinkles, Skin Aging
RecruitingPhase 3
Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
Skin Quality
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Skin Aging and Reproductive Aging, run by ChinaNorm at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 29 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Assessment (time frame: The assessment is performed as a single evaluation at the T1 (baseline) laboratory visit .). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.